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1. Introduction
One of the most common complications of pregnancy is early pregnancy failure, of which
25% result  in  miscarriages  and 1-2% ends in  ectopic  pregnancy.  Both these  entities  can
present with similar symptoms of abdominal pain and/or vaginal bleeding [1]. The most
common site  of  ectopic  pregnancy is  fallopian tube.  As tubal  ectopic  pregnancy (EP)  is
associated with high morbidity and mortality, early and accurate diagnosis of this condi‐
tion is warranted. Present protocols for diagnosis of ectopic pregnancy utilize serial serum
human  chorionic  gonadotropin  (β-hCG)  levels  and  pelvic  ultrasound  [2].  However,
distinction between an intrauterine or extrauterine pregnancy may not be possible in 8-31%
of cases at the first visit, even with sophisticated transvaginal ultrasound [3]. As a result,
multiple visits for serial β-hCG and ultrasound monitoring are required before a diagno‐
sis can be established and management initiated. This interim period of uncertainty may
lead  to  potential  life  threatening  complications  like  intra-abdominal  bleed  and  future
infertility because of compromised tubal integrity. Therefore, early diagnosis of tubal ectopic
not  only  prevents  the  added  mortality  in  patients,  but  also  plays  an  important  role  in
preventing future infertility. Also, the optimal management strategies for ectopic pregnan‐
cy and other abnormal intrauterine pregnancy (IUP) like miscarriages differ, and these two
distinct  clinical  entities  need  to  be  differentiated  at  the  early  stages  of  pregnancy.  A
circulating  serum  biomarker  may  aid  in  predicting  early  pregnancy  outcome  (viable
intrauterine pregnancy, miscarriage or tubal ectopic pregnancy), and may guide in deciding
the best management strategy (conservative, medical or surgical) for the patient. Numer‐
ous groups have focussed their attention on this issue, and have reported many potential
candidate  biomarkers.  The  present  chapter  discuss  the  recent  status  of  these  candidate
biomarkers in diagnosing tubal ectopic pregnancy, along with our experience, and attempt
to foresee the future diagnostic trend of this clinically significant entity.
© 2015 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.1. Problem statement
Tubal ectopic pregnancy is an important cause of early pregnancy failure attributing signifi‐
cantly to morbidity and mortality, in absence of expeditious diagnosis. Currently, the diagnosis
of ectopic pregnancy is based on combined ultrasonograhic findings and serial β-hCG levels.
However, low positivity rates in early gestational age and a need for repeated testing are major
limitations of these diagnostic procedures, leading to added risk of tubal rupture and intra-
abdominal bleed. Therefore, a circulating serum based biomarker, which could differentiate
tubal ectopic from viable intrauterine pregnancy and other abnormal gestation (miscarriages)
at the first visit of the patient, is the need of the hour.
1.2. Application area
A circulating serum based biomarker which could accurately predict the outcome of preg‐
nancy such as ectopic pregnancy, miscarriage and viable intrauterine pregnancy. This may be
used to diagnose tubal ectopic, decide the course of management (medical or surgical), and
may aid in monitoring the prognosis and response to treatment in patients. This advancement
in clinical diagnostic may help in significantly bringing down the maternal morbidity and
mortality associated with early pregnancy failure.
1.3. Research course
Due to paucity of suitable animal models of tubal ectopic pregnancy, biomarker researches
have mainly been carried out in cohorts of women with tubal ectopic, miscarriages and viable
intrauterine pregnancy (IUP).
1.4. Method used
Comprehensive literature search was carried out for identifying studies on women with
gestational age of less than 12 weeks in which serum markers were used to predict the outcome
of pregnancy. The databases used were Medline, Embase, CINAHIL and Cochrane library,
using key work search ectopic pregnancy”, “tubal pregnancy” alone and in combination with
“diagnosis”, “screening” and “biomarkers”. Only the articles published in English were
included and references of all selected articles were also thoroughly searched. All the studies
that assessed diagnostic accuracy were included.
1.5. Status
The factors deciding the fate of first trimester pregnancy, and hence the potential biomarkers
for tubal ectopic pregnancy can be systematically categorized into two groups-Markers related
to implantation site & milieu and Markers related to embryo (Fig 1). Important biomarkers in
both these categories are described
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Figure 1. Candidate biomarkers for Ectopic Pregnancy
2. Markers related to embryo
2.1. Markers of abnormal trophoblast function
Theses are the molecules secreted from the conceptus. It would be probable that the pregnancy
implanted in the ectopic environment will have abnormal growth kinetics that can be reflected
in disarrayed trophoblast function. The following markers have been described in this section:
1. Beta-human chorionic gonadotropin (β-hCG)
It is a glycoprotein hormone produced by trophoblast which maintains corpus luteum.
Currently, β-hCG is the only biomarker used clinically in the diagnosis of ectopic pregnan‐
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cy[4]. A doubling of serum β-hCG over 48 hours is suggestive of viable intrauterine pregnancy
[5]. If the levels remain static or fall, it is suggestive of early pregnancy failure, and the diagnosis
need to be confirmed by more invasive procedures like endometrial curettage or laproscopy.
To prevent unnecessary invasive procedures, studies suggested that the minimum rise of β-
hCG over 48 hours to predict normal viable intrauterine pregnancy can be reduced to 53% [6]
or 35% [7,8]. Another important concept in serum β-hCG estimation is the discriminatory zone,
that is the minimum β-hCG concentration at which an intrauterine gestational sac could be
reliably identified on ultrasound. The current discriminatory zone lies between 1500-3000
mIU/L [9]. Recently, a series of mathematical models incorporating β-hCG ratio (serum β-hCG
at 48 hours/ serum β-hCG at 0 hours) have been developed to predict early pregnancy outcome,
although it has not been sufficiently validated [10-13]. Another retrospective cohort study
observed that in addition to the two values of serum β-hCG at 0 and 48 hours, third β-hCG
evaluation on day 4 improved the accuracy of ectopic pregnancy prediction by 9.3% [14]. The
role of β-hCG has also been studied to predict response to therapy. A cut-off value of 2121
mIU/L of the initial serum β-hCG, has shown a specificity of 76.4% and a sensitivity of 80.56%
in predicting response to methotrexate therapy, with poor response below the cut-off [15].
Similarly, a cut-off of more than 1790mIU/ml was found to predict methotrexate treatment
failure by another group [16]. Presently, serial monitoring of β-hCG is in use for the diagnostic
triage of first trimester bleeding, but further studies are being conducted to use it in the
prognostic protocol of EP.
2. Hyperglycosylated hCG
Hyperglycosylated hCG (hCG-H) is a variant of hCG with four instead of two oligosaccharides.
The site of production is first trimester invading extravillous cytotrophoblast, where it
prevents trophoblast cell apoptosis [17,18]. Low proportions of hCG-H (< 50% of total hCG)
was shown to predict failed pregnancy [19,20]. Another study identified a cut-off of 13µg/L
for identifying failed pregnancy with 73% sensitivity and 98% specificity [21]. On the other
hand, Butler et al did not find a role of hCG-H in the diagnostic algorithm for EP [22]. Recent
study explored the role of hCG-H in predicting ongoing pregnancies after in vitro fertilization
and found that day 9 level of hCG-H > 110pg/ml was 96% specific for ongoing pregnancy [23].
Conflicting results regarding the use of hCG-H as a marker of preeclampsia have also been
reported [24,25]. Since, there is paucity of data on use of either concentration or proportion in
distinguishing ectopic pregnancy from miscarriage, further studies are required to validate its
usefulness as a biomarker for EP.
3. Activin A
Activin A is a dimeric glycoprotein of TGF-β superfamily, with a role in cytotrophoblast
invasion [26]. A study by Florio et al found Activin A level at a cut-off of ≤0.37ng/mL to have
100% sensitivity and 99.6% specificity for the diagnosis of EP [27]. Rausch et al found Activin
A to have 80% sensitivity and 72% specificity as a single marker in a cohort of patients with
EP [28]. Daponte et al also observed activin A concentrations to be significantly lower in
women with EP and women with missed abortion, compared to IUP, and reported that at a
threshold value of 505 pg/mL, activin A had 87.9% sensitivity and 100% specificity for
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discriminating an ectopic pregnancy from viable pregnancies [29]. On the contrary, Activin-
A was not found useful in diagnosing EP [30, 31]. Similarly, Elito et al demonstrated that serum
activin A levels could not discriminate between an EP from a normal intrauterine pregnancy
when an adnexal mass was found by transvaginal scan [32]. Therefore, A validation of this
biomarker in a larger cohort would be encouraged before makes it a tool for diagnostics.
4. Follistatin (FS)
Follistatin is a circulating protein produced from human placenta, with rising serum concen‐
tration throughout pregnancy [33, 34]. Follistatin is primarily involved in modulating the
biological activity of activin by binding to activin by high-affinity, which can neutralize the
majority of the actions of activin [35]. Daponte et al reported that the concentration of FS was
significantly lower in EP and MA compared to women with a viable IUP, and found that FS
was able to discriminate IUP from EP, But not miscarriage from EP [29].
5. Pregnancy associated plasma protein-A (PAPPA)
PAPPA is a glycoprotein produced by trophoblast. Normally, PAPPA is up-regulated by
progesterone, which promotes the adhesion and proliferation potential of trophoblastic cells
[36]. It has been extensively studied and used as a marker of screening for first trimester
aneuploidy [37]. Mueller et al found decreased levels of PAPPA in patients with ectopic
pregnancy when compared to normal viable intrauterine pregnancy [38]. Dumps et al found
a cut-off of <14.3 ng/ml to have a sensitivity of 64.5% with a 99% specificity for pregnancy
failure [39] But the levels were found to be lower in miscarriages making the discrimination
between EP and other abnormal intrauterine pregnancy dissatisfactory. On the other hand
Ugurlu et al and Daponte et al observed that PAPPA can differentiate abnormal pregnancy
from the viable normal IUP [40, 41]. Inconsistency in these results prompts us to study this
marker in greater details.
6. Pregnancy specific beta glycoprotein-1 (SP-1)
Pregnancy specific beta glycoprotein-1 (SP-1) is a secreted protein produced from syncytio‐
trophoblast, thought to be involved in immunomodulation [42]. In addition, recently it has
been observed that SP-1 induce transforming growth factor beta 1 (TGFB1), which among its
other diverse functions inhibits T-cell function and has proangiogenic properties [43]. SP1 has
also been reported as a first trimester maternal serum marker of small for gestational age (SGA)
and preterm delivery [44]. For early pregnancy failure, Tornehave et al found lower levels of
SP-1 to be suggestive of ectopic pregnancy [45]. Witt et al found a sensitivity of 65 % and a
specificity of 74 % by taking a cut-off of 103.3µg/ml [46]. Further studies are needed to validate
the use of SP-1 in EP.
7. Human placental lactogen (hPL)
Human placental lactogen is a circulating protein produced by the trophoblasts. Mueller et al
found hPL levels to be decreased in ectopic pregnancy [38], but Rausch et al and Daponte et
al found no difference in hPL levels between Ectopic pregnancy, abnormal IUP and normal
viable IUP [28,41]. hPL as a biomarker of EP has to be evaluated in larger cohort of patients.
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8. A disintegrin and metalloprotease-12 (ADAM-12)
ADAM-12 is a glycoprotein primarily produced by syncytiotrophoblast, with a role in
syncytial fusion [47]. ADAM-12 was found to be significantly decreased in patients with EP
when compared to viable IUP in a cohort of 199 patients [48]. Horne et al observed that when
measured in isolation, ADAM-12 levels had limited value as a diagnostic biomarker for EP
[49], whereas Yang et al observed low levels of ADAM12 in complete spontaneous abortion
and ectopic pregnancy compared to normal pregnancies [50]. Overall, this promising new
marker still requires large prospective cohorts for validation.
9. Placental micro-RNA
At least 31micro-RNA expressed from placenta have been isolated with various functions in
gene regulation[51,52]. Zhao et al found that microRNA miR-323-3p was found to be lower in
patients with EP as compared to those with normal IUP, yielding a sensitivity of 30% and a
specificity of 90% in the diagnosis of ectopic pregnancy [53]. This is another promising area of
biomarker discovery with further studies being conducted.
10. Placental mRNA
Placental mRNAs secreted by trophoblasts can be altered in early pregnancy failure, and
therefore have been studied recently for their diagnostic potential in EP. A recent case-control
study conducted by Takacs et al demonstrated that patients with EP have significantly lower
copy numbers of hCG and hPL mRNA in plasma compared to viable IUP [54]. Placental mRNA
have also been studied for viability and chromosomal aneuploidy [55,56]. Evaluation of
changes in placental mRNA expression may serve as a potential biomarker in future for
detecting early pregnancy failures.
11. Alpha feto protein (AFP)
AFP is a produced from both yolk sac and fetal liver with a role analogous to adult albumin
[57]. Grosskinsky et al found AFP to be elevated in EP, whereas Kuscu et al study contradicted
these findings [58, 59]. In our experience, we observed AFP concentration to be elevated in
women with miscarriages when compared to normal IUP, but found it to be decreased in
women with tubal ectopic compared to both IUP and miscarriages. ROC analysis in our study
revealed that AFP was able to discriminate between miscarriage and ectopic, as well as
between IUP and ectopic [Unpublished data].
12. Cell free fetal DNA
Cell free fetal DNA escaping into the maternal circulation has also been evaluated as a marker
of early pregnancy failure. Lazar et al estimated the cell-free foetal DNA of the Sry gene, and
observed its concentration to be significantly higher in those with a tubal ectopic pregnancy.
At a cut-off of more than 80 GE/ml, cell free fetal DNA was able to differentiate a tubal ectopic
from an intrauterine pregnancy with sensitivity of 84%, a specificity of 76% [60]. As the
technology at present is cumbersome, its utility as a useful serum biomarker in a clinical setup
has been limited.
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2.2. Markers of abnormal corpus luteal function
These are the markers for the evaluation of luteal function by measuring secreted products
from the ovary. As the continuous function of the corpus luteum is essential for the mainte‐
nance of early pregnancy, these functions may be suboptimal in ectopic pregnancy, and can
be measured for diagnostic usage.
1. Progesterone
Maternal progesterone is initially produced by corpus luteum followed by placenta, and
ensures appropriate development of the endometrium, uterine growth, adequate uterine
blood supply, and preparation of the uterus for labor [60]. Progesterone levels are found to be
low in both ectopic pregnancy and other abnormal IUP, when compared to viable IUP [62].
Extensive studies have been performed for the use of progesterone both as a single marker
and in multiple marker settings to diagnose EP. A recent meta-analysis of 26 cohort studies,
including 9436 pregnant women observed that at a cut-off values from 3.2 to 6 ng/mL,
progesterone predicted a non-viable pregnancy with sensitivity of 74.6% and a specificity of
98.4%, although it was not able to distinguish EP from other abnormal IUP [63]. Similar results
were observed by the meta analysis performed by Mol et al with a progesterone cut-off of <5ng/
ml [64]. In our experience of the cohort of women, progesterone concentration was significantly
lower in woman with ectopic pregnancy and women with miscarriages compared to patients
with normal IUP. We observed a cut-off of <4.6ng/ml, to have a sensitivity of 93.3% and a
specificity of 96.7% in differentiating EP from viable IUP, and a a cut-off of <12ng/ml, to have
a sensitivity of 92.8% and a specificity of 90% in differentiating miscarriages from viable IUP,
but found progesterone to be unable to discriminate between EP and other abnormal IUP
[Unpublished data]. Also, high progesterone does not rule out EP in a patient with inconclusive
ultrasound findings. Therefore, further large scale studies are required to study the utility of
progesterone as a single marker or as a part of multiple markers to diagnose EP with acceptable
sensitivity and specificity.
2. Oestradiol
Oestradiol (E2) is another important steroid secreted from the corpus luteum of pregnancy in
response to hCG and could serve as a marker of pregnancy dynamics. Guillaume at al observed
in his preliminary study that all of the EP patients had an E2 level of less than 650 pg/ml giving
a sensitivity of 100% and specificity of 99% [65]. Witt et al however, did not find any difference
in serum E2 when women with EP were compared with those with nonviable intrauterine
pregnancies [46]. Mantzavinos et al on the other hand reported that E2 concentrations rose
continuously in viable pregnancies, whereas in EP the values plateaued after the sixth week
and declined after the eighth week of gestation [66]. However, as the concentrations of serum
oestradiol have a considerable overlap among various clinical studies, this marker has not been
put into clinical use.
3. Inhibin A
Inhibin A is a dimeric protein produced from corpus luteum [67]. Seifer et al observed lower
levels of inhibin-A in EP compared to normal viable IUP [68]. Further, Segel et reported that
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at a cut-off of 50 pg/mL, Inhibin-A had 100% sensitivity and specificity for diagnosing EP
compared to viable IUPs, but found decrease in both sensitivity and specificity when patients
of EP were compared with those of other abnormal IUP [69]. Similarly, Rausch et al found
Inhibin A to have a sensitivity of 83% and a sensitivity of 79% at a lower cut-off of 23.67pg/ml
in discriminating EP from viable IUP [28]. In contrast to the above findings, Chetty et al found
Inhibin-A to be unable to discriminate EP from viable IUP in their cohort of 109 patients [70].
It can be concluded that although Inhibin-A is a promising marker for the early pregnancy
viability, further studies need to be carried out to use it as a biomarker in the detection of EP.
4. Relaxin and renin
Relaxin is a peptide hormone produced by the corpus luteum of pregnancy, which is elevated
shortly after conception and remain steady until the 15th week of gestation [71]. Garcia et al
observed a lower levels of serum relaxin concentrations in patients with EP than that in those
with a viable IUP [72]. On the other hand, Witt et al found relaxin to be poorly discriminatory
as a biomarker of ectopic pregnancy [46].
Renin is another peptide produced by ovaries and the production rises after pregnancy [73].
Meunier et al reported that active renin was significantly decreased in women with EP when
compared with those with an ongoing IUP or spontaneous miscarriage, however because of
its low specificity and sensitivity, the use of renin in the clinical setting has been limited [74].
2.3. Markers of angiogenesis
1. Vascular Endothelial Growth Factor (VEGF)
VEGF plays an important role in the angiogenesis of the fetomaternal unit [75]. It has been
reported that maternal serum VEGF concentrations are associated with depth of trophoblastic
penetration into the tubal wall [76]. A case control study observed a cut-off of 200pg/ml had a
sensitivity of 60% and a specificity of 90 % in predicting EP [77]. Similar findings were observed
by Felemban et al [78]. Daponte et al observed a sensitivity of 78% and a specificity of 100 %
in predicting EP at a cut-off of 174.5pg/ml. [41]. Recently Fernandes et al reported that serum
level of VEGF was significantly higher in women with EP, and when threshold concentrations
of serum VEGF level > 200 pg/ml were used, an EP could be distinguished from a normal
pregnancy with a sensitivity of 51.4%, a specificity of 90.9% [79]. On the contrary, Rausch et al
found no difference in the levels of VEGF between EP, abnormal IUP and viable IUP [28]. The
variations in the study results of VEGF shows that further investigations are required to
ascertain its suitability as a biomarker for EP.
2. Placental like growth factor (PlGF)
PIGF is a pro-angiogenic growth factor produced by the trophoblast at the site of implantation
[80]. Horne et al reported the expression of PIGF m-RNA to be lower in trophoblastic cells in
patients with EP as compared to those with viable IUP [81]. Daponte et al later observed that
at a PIGF level of more than 15.73pg/ml could differentiate viable pregnancy from early
pregnancy failures including EP and abnormal IUP with reasonable sensitivity and specificity,
but could not differentiate among them [82]. Recent report by Martínez-Ruiz et al also didn't
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find significant differences for PlGF between EP and viable IUP [83]. Therefore, there is a need
of validation of this marker in a larger cohort.
3. Angiopoietins
Angiopoietins are proteins which belong to the family of angiogenic proteins, which has been
shown to be critically involved in the process of placental maturation and growth from early
pregnancy. Angiopoietin-1 (Ang-1) and Ang-2 are two critical regulators with different
functions of vascular development and angiogenesis [84, 85]. Daponte et al reported Ang-1
and Ang-2 concentrations and their ratio to be lower in EP compared to IUP. They also found
the trophoblastic Ang-1 mRNA expression levels to be lower in EP compared to IUP, while
Ang-2 mRNA was found to be higher in EP than in IUP [86]. Schneuer et al in their recent study
suggested that the lower Ang-1/Ang-2 ratio in first trimester is associated with most adverse
pregnancy outcomes, but do not predict outcomes any better than clinical and maternal risk
factor information [87].
2.4. Markers related to normal uterine implantation
These biomarkers are released into the circulation as a result of normal interaction between
the pregnancy and the uterine decidua. As the normal process is disrupted in EP, these
surrogate markers can be used to diagnose EP.
1. Leukemia inhibitory factor (LIF)
LIF is a cytokine of interleukin-6 family with a key role in implantation [88]. Wegner et al
observed that women with ectopic pregnancy had low serum concentrations of LIF and could
diagnose it with moderate sensitivity and specificity [89]. However, Daponte et al failed to
find any difference in LIF concentrations in patients with ectopic pregnancy and other
abnormal intrauterine pregnancy [41]. A further attempt in validation of LIF has yielded
conflicting results. Mueller et al found LIF levels to be undetectable in serum of patients with
ectopic pregnancy and viable intrauterine pregnancy [38], whereas Iyibozkurt AC et al found
increased levels of LIF in patients with EP compared to IUP [90]. Increased immunohisto‐
chemical expression of LIF in fallopian tube was found to be increased in EP compared to non
–pregnant and healthy pregnant controls, indicating its role in ectopic implantation of embryo
[91]. Similarly it was observed that LIF expression was increased in inflamed fallopian tube
and might be one of the reasons of increased susceptibility of salphingitis patients to EP [92].
2. Glycodelin (Placental protein 14)
Glycodelin is secreted from endometrium and fallopian tube, with immunomodulatory role
in implantation. Its serum concentration increases during early first trimester of pregnancy,
till 8-10 weeks of gestation and then progressively declines [93, 94]. Foth et al found signifi‐
cantly lower levels of serum glycodelin in patients with ectopic pregnancy compared to IUP
and incomplete abortion with a study population of 169 subjects [95]. Out of the three groups,
who studied glycodelin in a multiple marker setting, two had found glycodelin levels to be
decreased in EP, while one observed no significant difference between EP and abnormal IUP
[28, 38, 41]. Further studies are required to validate the use of this marker in EP.
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3. Mucin-1 (Muc-1)
Muc-1 is a glycoprotein expressed by endometrium and fallopian tube epithelium involved in
implantation [96]. Muc-1 expression was observed to be lower in luminal epithelial of tubes
with ectopic pregnancies [97]. Similar findings were observed by Reefaat et al [98]. However,
the role of serum Muc-1 as a diagnostic modality has not been studied in much detail.
4. Adrenomedullin
Adrenomedullin is a peptide hormone belonging to calcitonin/calcitonin gene related peptide,
and is thought be involved in endometrial angiogenesis. Liao et al found plasma and oviductal
tissue adrenomedullin to be lower in EP and suggested that this decreases ciliary beating and
muscle contraction leading to retained embryo and its implantation in the oviduct [99]. Similar
findings were observed in nasal epithelium in patients of tEP by the same group [100]. Further
studies are required to explore the possible role of serum adrenomedullin as a diagnostic
marker for EP.
5. Activin B
Activins, dimeric proteins of transforming growth factor-beta (TGF-b), have recently been
found in gonadal fluid with growth factor like actions [101]. It is produced by many organs
including pituitary gland, gonads, placenta etc. It has been shown to promote decidualization
of the endometrium during pregnancy [102]. Consequently low serum activin levels have been
associated with ectopic pregnancy. Although recent studies have mainly focussed the role of
serum activin A as a potential marker of ectopic pregnancy, limited literature is available
regarding the role of activin B in-spite of the experimental evidence of differential effect of
activin B on decidua. In our population, we observed that the concentration of activin B in
maternal serum to be significantly lower in patients with tEP compared to those with normal
IUP [Unpublished data]. Similar results were observed by Horne et al, who found decreased
expression of activin B in endometrium along with decreased serum levels of activin B with
normal levels of progesterone in 11 women with tEP [103]. Activin B is a new, though prom‐
ising marker for EP diagnostic triage.
3. Markers related to tubal implantation
3.1. Markers of compromised tubal musculature markers
These markers reflect the disruption of the integrity of the tubal circular smooth muscle layer,
which can happen in an ectopic implantation. These markers of muscle damage have been
investigated as biomarkers for diagnosing EP.
1. Creatine Kinase (CK)
Creatine Kinase is the enzyme released from damaged muscles, which is currently used in the
diagnosis of myocardial infarction. Lavie et al found serum CK levels to be significantly higher
in patients with tEP as compared to those with missed abortion or normal IUP [104]. Similar
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findings were observed by Birkhahn et al and Duncan et al [105,106]. In a study conducted in
our population, we found that the optimal cut-off for total CK, CK-MM and CPK-MB% as
predictors of ruptured EP were 147 IU/L, 135 IU/L and 10%, respectively, with the former two
having higher specificity, and latter high sensitivity [107]. On the contrary, several independ‐
ent study groups found CK to be inadequate in diagnosing EP [108-112]. Recently, Safdarian
et al studied the role of CK-1 as an indicator for differentiating between the successful and
unsuccessful treatment groups in EP, but failed to find any relation between initial CPK serum
levels [113].
2. Smooth muscle heavy-chain myosin (SMHC) & Myoglobin
Smooth muscle heavy chain myosin and myoglobin are markers of smooth muscle damage.
As the ectopic pregnancy grows to invade the muscular layer of the fallopian tube, markers
of muscle damage should also rise. Birkhahn et al studied serum myoglobin and smooth
muscle heavy-chain myosin and observed a statistically significant elevation in the serum
levels of SMHC, but did not find it  useful in the screening for EP [105,114].  As there is
paucity  of  data  regarding the  usefulness  of  these  markers  in  the  screening of  EP,  their
clinical utility is limited.
3.2. Markers of inflammation and peritoneal irritation
EP can lead to inflammation and peritoneal irritation and the following biomarkers have been
investigated as an potential biomarkers of the same process.
1. Circulating cytokines
Several cytokines as marker of peritoneal inflammation has been reported including IL-2R,
IL-6, IL-8, IL-10, IL-11, IL-15 and TNF-α. Soriano et al observed increased concentration of IL-6,
IL-8 and TNF-α in patients with EP compared with normal and abnormal IUP. IL-8 at a cut-
off of >40 pg/ml was shown to have a sensitivity and specificity of 82.4% and 81.8 % respectively
in diagnosing EP [115]. Experience in our population regarding IL-6 & IL-8 levels, we observed
that the level of IL-6 shows a significant increase in the women with tubal ectopic pregnancy
in comparison to intrauterine abortion and normal pregnancy. It was also seen that IL-8 levels
decrease significantly in the tubal ectopic pregnancy cases and in intrauterine abortion patient
when compared to the normal pregnancy group. ROC analysis revealed that at the cut-off of
26.48pg/ml of IL-6 level predict the probability of tubal ectopic pregnancy with 53.57%
sensitivity, 80%specificity [Unpublished paper]. Similar observations were made by Rausch
et al, who observed lower values of IL-8 and TNF-α in women with EP, whereas no significant
difference was observed in the IL-6 levels between EP and viable IUP [28]. No difference has
been observed in the levels of IL-10 and IL-11between EP and viable IUP [90]. IL-15 has also
been studied as it is expressed by human placental tissue culture and it is maximally expressed
during the implantation period in the deciduas. Daponte et al reported that IL-15 concentra‐
tions were significantly higher in women with EP compared to patients with IUP, and found
IL-15 to have high diagnostic accuracy for the discrimination of a viable IUP from an EP with
an area under the curve of 0.818 [116].
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2. CA-125
Conflicting results have been reported by several groups regarding the status of circulating
CA-125 in EP with some groups reporting an increase, some decrease and few found no
difference between viable IUP and EP [117-121]. In our experience in the cohort of patients,
we found CA125 concentration to be significantly higher in woman with miscarriages
compared to patients with normal IUP, but not in women with ectopic compared to IUP
[Unpublished paper]. Women with IU abortion were found to have significantly higher
CA-125 levels, compared to the other two groups. Katsikis et al also reported that when using
CA-125 concentration of more than 41.9 U/ml as a threshold for the diagnosis of IU abortive
pregnancy, sensitivity was 80% and specificity was 87% for discriminating it from EP [122].
3. Antibodies to C1q complement
C1q complement has been shown to promote trophoblast invasion of deciduas, a crucial step
in normal placental development. Animal models have demonstrated that the lack of C1q is
characterized by poor trophoblast invasion and pregnancy failure [123,124]. Studies based on
these observations have measured the levels of antibodies to C1q complement in early
pregnancy failure have been conducted. Daponte et al failed to observe any difference between
normal viable IUP, EP and other abnormal IUP [116]. As new studies would be undertaken by
different groups, more information regarding this marker is likely to emerge.
The biomarkers studied in ectopic pregnancy with their current status are summarized in
table 1.
Sl
No Biomarker Cut-off Sensitivity Specificity Reference
1 Β-hCG
a. Single serum levels <2000mIU/ml 87% 39% Shaunik et al 2011
b. 48 hours rise <53% rise
<35% rise
91%
83.2%
66.6%
70.8%
Barnhart 2004
Morse 2012
c. Mathematical models
M1 0.21 83% 88% Condous 2004
M4 - 92% 91% Condous 2007
31% 98% Kirk 2006
81% 89% Barnhart 2010
2 Hyperglycosylated hCG 13µg/L 73% 98.1% Sutton-Riley 2006
3 Pregnancy associated plasma
protein-A (PAPPA)
0.53 ng/ml 81% 54% Rausch 2011
4 Pregnancy specific beta
glycoprotein-1 (SP-1)
103.3µg/ml 65% 74% Witt 1990
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No Biomarker Cut-off Sensitivity Specificity Reference
5 ADAM-12 48.49ng/ml 97% 37% Rausch 2011
6 Activin A 0.37ng/ml
0.38 ng/ml
0.26 ng/ml
505 pg/ml
100%
80%
59.6%
87.9%
99.6%
72%
69%
100%
Florio 2007
Rausch 2011
Warrick 2012
Daponte 2013
7 Progesterone 3.2-6 ng/ml
5ng/ml
10.75 ng/ml
74.6%
95%
85%
98.4%
40%
85%
Verhaegen 2012
Mol 1998
Katsikis 2006
8 Oestradiol 650 pg/ml 100% 90% Guillaume 1990
9 Inhibin A 50 pg/ml
28.67 pg/ml
100%
83%
100%
79%
Segel 2008
Rausch 2011
10 VEGF 200 pg/ml
174.5 pg/ml
200 pg/ml
28.24 pg/ml
60%
78%
88%
95%
90%
100%
100%
50%
Daniel 1999
Daponte 2005
Felemban 2002
Rausch 2011
11 PIGF 15.7 pg/ml 86% 73% Daponte 2011
12 LIF 6.2pg/ml 73% 72% Wegener 2001
13 Interleukin-8 40 pg/ml 82.4% 81.8% Soriano 2003
14 Interleukin-15 16.1 pg/ml 92% 68% Daponte 2013
Table 1. Current status of biomarkers of tubal Ectopic pregnancy
4. Further research
Since the factors and their interplay involved in maintenance of normal viable pregnancy are
not completely understood, various approaches have been explored in biomarker discovery
including unbiased proteomics, shotgun proteomics [125,126]. The challenges in biomarker
discovery include the variability of biomarkers with gestational age, impact of coexistent
morbidities like hypertension, diabetes, chromosomal anomalies on biomarker levels and their
interpretation. Other emerging markers studied in ectopic pregnancy include: Endocannibi‐
noid system abnormalities in the form of high anandamide levels and reduced receptor
expression have been implicated, in women with ectopic pregnancy [127,128].
Brown et al conducted a proteomics study and identified fibronectin has ability to discriminate
EP from other pregnancy outcomes suggesting its diagnostic potential and its use as an adjunct
to future multiplex EP diagnostic tests [129].
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Serum Macrophage Inhibitory Cytokine-1 levels were found to be lower in women with
histologically confirmed EP compared to women with definite viable intra-uterine pregnancy
by Skubisz et al [130].
Another recent study by Beer et al that screened the proteome of a small group of women with
EP and controls identified potential novel biomarkers, including ADAM-12 and ISM2 (Isthmin
2) as well as five specific isoforms of pregnancy-specific beta-1-glycoprotein 131].
5. Use of multiple biomarkers in ectopic pregnancy
As maintenance of a viable pregnancy requires an interplay of multiple factors, no single
marker has been used successfully as a biomarker for EP. It seems prudent, therefore, to
combine these markers and use them in the multiple marker setting. Rausch et al demonstrated
that a four-marker test including Progesterone, VEGF, Inhibin A, and Activin A could predict
EP with 100% accuracy in those with an hCG<1500 mIU/mL [28]. Further studies are necessary
to fully assess the discriminatory capacity of such a test. Similarly, Feng et al found a combi‐
nation of Δβ-hCG, Progesterone and Oestradiol to be helpful in distinguishing EPs and normal
IUPs, facilitating earlier diagnosis and the timely implementation of medical treatment to
prevent tubal rupture [132].
Soriano et al found that the combination of inflammatory cytokines IL-6, IL-8, and TNF-alpha
was able to predict EP with specificity of 100%, but sensitivity of 52.9% [115].
Another group in Switzerland developed a multiple marker test, the “triple marker analysis”
[VEGF/(PAPP-A X P)] had a sensitivity of 97.7% with a specificity of 92.4% in diagnosing
EP [38].
In another study, investigators studied serum levels of 17β-estradiol (E2), progesterone (P4),
testosterone (T), beta-human chorionic gonadotropin (β-hCG), vascular endothelial growth
factor-A (VEGF-A), placental growth factor (PIGF), and a distintegrin and metalloprotease
protein 12 (ADAM12) in different patient groups with no definite results [133].
6. Conclusion
Novel biomarker of ectopic pregnancy with adequate sensitivity and specificity could assist
in early diagnosis and hence timely intervention, thereby dramatically reducing the morbidity
and mortality. There are number of potential molecules for use as biomarkers in women at risk
for EP. As no single biomarker is ready for use in clinical setting, more prospective cohorts
including ectopic pregnancy, normal and abnormal IUPs are required to validate these
markers. Also, it would be prudent to concentrate the efforts on developing a panel of markers
which include markers of viability, location of implantation and fetal milieu. Recent times have
witnessed positive developments in this field, but lot of validation is required before a marker
can be used independently in clinical setting.
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